Lyell Immunopharma, Inc. ( LYEL) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM EST ...

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius ...

A first-in-class gene-regulating therapy cut seizures by up to 91% in children with Dravet syndrome in extension studies, ...

The FDA has approved Johnson & Johnson’s TECVAYLI plus DARZALEX FASPRO for the treatment of adults with relapsed or refractory multiple myeloma.

On Thursday, the U.S. Food and Drug Administration approved Johnson & Johnson‘s JNJ Tecvayli in combination with Darzalex ...

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ...

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

In second- or later-line setting, combination cut risk of disease progression or death by ...

From analytical control through downstream processes to manufacturing, BsAbs present challenges in protein expression, purity, and stability.

Teclistamab plus daratumumab hyaluronidase-fihj has been approved for patients with relapsed/refractory multiple myeloma as ...

Patients with advanced/refractory cancers treated with genomically matched therapies had better overall survival only when ...

KOMZIFTI FDA launch, early revenue, payer coverage, AML expansion plans, cash runway and 2026 outlook—read now.